30 results about "Blood markers" patented technology

The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient.The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor assoicated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal.

The present invention provides methods for early diagnosis of amyotrophic lateral sclerosis (ALS) and for determining the efficacy of a treatment for ALS in an ALS patient, i.e., monitoring ALS progression, utilizing cellular blood markers; as well as kits for carrying out these methods.

The present invention relates to a composite marker for diagnosis of diabetic retinopathy and a use thereof and, more particularly, to a composite marker, for diagnosis of diabetic retinopathy, comprising two or more blood markers specific for diagnosis of diabetic retinopathy and thus having an improved diagnostic performance. In addition, the present invention relates to a composition for diagnosis of diabetic retinopathy, a diagnostic kit, and a method for providing information necessary for diagnosing diabetic retinopathy, each of which uses the composite marker. The composite marker for diagnosis of diabetic retinopathy of the present invention was found to be superior to combinations of other markers in terms of sensitivity and diagnosis performance and to exhibit a high diagnostic potential for initial diabetic retinopathy, as analyzed for combinations between protein quantitation values of the composite marker and fundamental clinical information. In addition, the composite biomarker of the present invention does not use blood proteins for biopsy, but can conveniently perform analysis by means of patient plasma and thus can be advantageously applied to the early diagnosis of diabetic retinopathy.

The present invention relates to a composite marker for diagnosis of age related macular degeneration (AMD) and a use of same and, more specifically, to a composite markers for diagnosis of age related macular degeneration, which consists of two or more blood markers specific to diagnosis of age related macular degeneration and has improved diagnostic performance. In addition, the present invention relates to a composition for diagnosis of age related macular degeneration, a diagnostic kit, and a method for providing information necessary for diagnosing age related macular degeneration, each of which uses the composite marker. The composite marker for diagnosis of age related macular degeneration of the present invention was found to be superior to combinations of other markers in terms of sensitivity and diagnosis performance and to exhibit a high diagnostic potential for both initial and late macular degeneration, as analyzed for combinations between protein quantitation values of the composite marker and fundamental clinical information. In addition, the composite marker of the present invention does not use blood proteins for biopsy, but can conveniently perform analysis using patient plasma and as such, can be advantageously applied to the early diagnosis of age related macular degeneration.

The invention discloses a punching device for blood standard card sampling, comprising: a bracket; a driving part, the driving part is installed on the bracket; a buffer part, the buffer part includes a buffer plate and a buffer spring, and the buffer plate can move along the Z axis Installed on one end of the bracket, the buffer spring is installed between the buffer plate and the bracket; and the tine, the tine is fixed on the buffer plate, the tine can move along the Z axis and is placed on the bracket, the tine The extruding end away from the needle tip is located in the bracket, and the driving part is used to drive the perforating needle to move along the Z axis to punch holes. Since the driving part is installed on the bracket, the driving part can be used to drive the punching to punch holes for the blood label card, realizing automatic punching, improving the efficiency and accuracy of punching, and the punching needle is installed on the buffer plate, and the buffer plate is connected with the punching plate. A buffer spring is installed between the brackets, and the buffer spring can effectively relieve the impact force when the tine is punched, play the role of buffering and shock absorption, and improve the service life of the tine.

The invention discloses a lung cancer model for the combined detection and diagnosis of peripheral blood methylation gene and IDH1. The invention provides the application of methylated SHOX2 gene, methylated PTGER4 gene and IDH1 protein as markers in the preparation of products for diagnosis or auxiliary diagnosis of lung cancer, and constructs a lung cancer model combined with three markers. Experiments have proved that compared with the single factor included, the diagnostic efficiency of the combined diagnosis model of the present invention is significantly enhanced. Therefore, the diagnostic efficiency of lung cancer can be improved by joint detection of blood markers.

The present invention provides the use of cellular blood markers for early diagnosis of Alzheimer's disease and for determining the efficacy of treatments for Alzheimer's disease in Alzheimer's patients (ie, monitoring Alzheimer's disease progression). ); and kits for carrying out these methods.